HIGHLIGHTS
- who: Chuan Zhang from the European Institute of (IEO), Italy The Ohio State University have published the research: Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review, in the Journal: (JOURNAL) of March/26,/2021
- what: The present systematic review of 24 health economic studies was conducted, which revealed that the existing cost-effectiveness analysis studies are generally of moderate reporting quality and that the modeling methods used in these studies need to be further strengthened for efficacy, in order to achieve valid outcomes to better support relevant . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.